BioStock: Ultimovacs in the fight against Melanoma

Report this content

Melanoma is the deadliest form of skin cancer. As such, new treatments for the disease are in strong demand. Norwegian immuno-oncology experts Ultimovacs are developing a type of cancer vaccine able to boost a patient’s immune system during cancer, and their top candidate UV1 is being tested in a phase I clinical trial and a phase II proof-of-concept study with different combination therapies in malignant melanoma patients. BioStock was able to get in touch with the company’s CMO Jens Bjørheim, and Senior Medical Advisor Steinar Aamdal to learn more about the disease and the phase I study, which recently produced results.

Read the full interview with Steinar Aamdal and Jens Bjørheim at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

BioStock: Ultimovacs in the fight against Melanoma
Tweet this